Table 3:
Base case clinical outcomes for the broad CKD population.
| Outcome | Dapagliflozin plus standard therapy | Standard therapy | Incremental |
|---|---|---|---|
| Mean time in each CKD stage, years | |||
| CKD G1 | 2.96 | 2.62 | 0.34 |
| CKD G2 | 6.16 | 5.77 | 0.39 |
| CKD G3 | 3.36 | 3.18 | 0.18 |
| CKD G4 | 2.40 | 2.23 | 0.17 |
| CKD G5 (pre-KRT) | 1.28 | 1.30 | –0.02 |
| Dialysis | 0.18 | 0.19 | –0.01 |
| Transplant | 0.71 | 0.75 | –0.03 |
| Event incidence, per 1000 patients | |||
| HHF | 119 | 140 | –21 |
Note that results are presented for the UK setting, there will be some variation in outcomes owing to the application of country-specific life tables.